Shopping Cart
- Remove All
Your shopping cart is currently empty
GZD856 formic is a potent, orally active inhibitor of PDGFRα/β and Bcr-Abl T315I, demonstrating IC50 values of 68.6 nM and 136.6 nM for PDGFRα/β, respectively, and 19.9 nM and 15.4 nM for native Bcr-Abl and the T315I mutant, respectively. This compound exhibits significant antitumor activity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,520 | 4-6 weeks | |
| 50 mg | $1,980 | 4-6 weeks | |
| 100 mg | $2,500 | 4-6 weeks |
| Description | GZD856 formic is a potent, orally active inhibitor of PDGFRα/β and Bcr-Abl T315I, demonstrating IC50 values of 68.6 nM and 136.6 nM for PDGFRα/β, respectively, and 19.9 nM and 15.4 nM for native Bcr-Abl and the T315I mutant, respectively. This compound exhibits significant antitumor activity. |
| Targets&IC50 | PDGFRβ:136.6 nM, PDGFRα:68.6 nM, Bcr-Abl:19.9 nM, BCR-ABL (T315I):15.4 nM |
| Molecular Weight | 578.58 |
| Formula | C30H29F3N6O3 |
| Cas No. | 2804039-78-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.